Novartis to Launch New Trials for Sluggish Entresto

May 20, 2016

Novartis has announced "the largest global clinical program" for heart failure as it subjects recently-approved Entresto to a battery of new trials.

FDA-approved in July 2015, Entresto has faced concerns from doctors over switching patients to the drug when they are stable on older medicines, leading to disappointing sales. Novartis now expects $200 million in 2016 sales -- well behind initial forecasts.

The new program, called "Fortifying Heart Failure Clinical Evidence and Patient Quality of Life" or "FortiHFy", will include 40-plus trials in 50 countries over five years. Trials are also aimed at expanding Entresto's treatment label to additional kinds of heart failure and for patients after a heart attack.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments